Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Background On the basis of promising results that were reported in several phase 2 trials,
we investigated whether the addition of the monoclonal antibody rituximab to first-line …
we investigated whether the addition of the monoclonal antibody rituximab to first-line …
Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia
Rituximab (RTX, anti-CD20 antibody) combined with chemotherapy is currently standard
treatment for chronic lymphocytic leukemia (CLL). Serum level of IL-8 is a prognostic factor …
treatment for chronic lymphocytic leukemia (CLL). Serum level of IL-8 is a prognostic factor …
Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG‐CLL4 (ML 21283) trial
T Robak, J Błoński, AB Skotnicki… - European journal of …, 2018 - Wiley Online Library
Objectives PALG CLL 4 is the first, randomized, phase III b study with rituximab, cladribine,
and cyclophosphamide (RCC) induction and subsequent maintenance with rituximab in …
and cyclophosphamide (RCC) induction and subsequent maintenance with rituximab in …
Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
C De Romeuf, CA Dutertre… - British Journal of …, 2008 - Wiley Online Library
Patients with chronic lymphocytic leukaemia (CLL) treated with a combination of fludarabine,
cyclophosphamide and rituximab show a high response rate. However, only a poor …
cyclophosphamide and rituximab show a high response rate. However, only a poor …
[HTML][HTML] Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic …
CC Mo, N Njuguna, PV Beum, MA Lindorfer, B Vire… - …, 2013 - ncbi.nlm.nih.gov
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic
lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based …
lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based …
[HTML][HTML] Subcutaneous rituximab in combination with fludarabine and cyclophosphamide for patients with CLL: initial results of a phase Ib study (SAWYER [BO25341]) …
Abstract 1637 Rituximab in combination with fludarabine and cyclophosphamide (FC) is
recommended as the standard treatment for patients (pts) with chronic lymphocytic leukemia …
recommended as the standard treatment for patients (pts) with chronic lymphocytic leukemia …
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab
L Reslan, S Dalle, S Herveau, E Perrial… - Leukemia & …, 2014 - Taylor & Francis
Monoclonal antibodies (MAbs) are becoming an essential component of the treatment of
patients with chronic lymphocytic leukemia (CLL). CLL is a heterogeneous disease with a …
patients with chronic lymphocytic leukemia (CLL). CLL is a heterogeneous disease with a …
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells
G Krause, M Patz, P Isaeva, M Wigger, I Baki, V Vondey… - Leukemia, 2012 - nature.com
Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia and is
characterized by the accumulation of long-lived B lymphocytes. Despite significant advances …
characterized by the accumulation of long-lived B lymphocytes. Despite significant advances …
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic …
JC Byrd, BL Peterson, VA Morrison… - Blood, The Journal …, 2003 - ashpublications.org
Recent studies have suggested that rituximab has clinical activity and modulates
antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia …
antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia …
[HTML][HTML] Rituximab and high-dose methylprednisolone for the initial treatment of chronic lymphocytic leukemia is associated with promising clinical activity and minimal …
AF James, JE Castro, JD Sandoval-Sus, S Jain, J Bole… - Blood, 2008 - Elsevier
Myelosuppression is associated with significant morbidity and mortality in chronic
lymphocytic leukemia (CLL) and is often exacerbated by currently available treatments for …
lymphocytic leukemia (CLL) and is often exacerbated by currently available treatments for …